{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T05:26:48Z","timestamp":1792301208151,"version":"4.4.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.thromres.2013.06.011","type":"journal-article","created":{"date-parts":[[2013,7,5]],"date-time":"2013-07-05T19:45:28Z","timestamp":1373053528000},"page":"e77-e82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cystatin C and creatinine as markers of bleeding complications, cardiovascular events and mortality during oral anticoagulant treatment"],"prefix":"10.1016","volume":"132","author":[{"given":"Marcus","family":"Lind","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-H\u00e5kan","family":"Jansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torbj\u00f6rn K.","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisbeth Slunga","family":"J\u00e4rvholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2013.06.011_bb0005","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0140-6736(60)92299-6","article-title":"Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial","volume":"1","author":"Barritt","year":"1960","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2013.06.011_bb0010","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1001\/jama.1976.03270140029017","article-title":"Mortality in patients treated for pulmonary embolism","volume":"236","author":"Alpert","year":"1976","journal-title":"JAMA"},{"key":"10.1016\/j.thromres.2013.06.011_bb0015","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1001\/archinte.1987.00370090041008","article-title":"Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study","volume":"147","author":"Wolf","year":"1987","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.thromres.2013.06.011_bb0020","doi-asserted-by":"crossref","first-page":"160S","DOI":"10.1378\/chest.08-0670","article-title":"Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Ansell","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.thromres.2013.06.011_bb0025","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2013.06.011_bb0030","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Bauersachs","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2013.06.011_bb0035","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","article-title":"Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation","volume":"285","author":"Gage","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.thromres.2013.06.011_bb0040","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1093\/eurheartj\/ehq278","article-title":"Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)","volume":"31","author":"Camm","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.thromres.2013.06.011_bb0045","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1056\/NEJMoa041365","article-title":"Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction","volume":"351","author":"Anavekar","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2013.06.011_bb0050","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1056\/NEJMoa0707064","article-title":"Use of multiple biomarkers to improve the prediction of death from cardiovascular causes","volume":"358","author":"Zethelius","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2013.06.011_bb0055","doi-asserted-by":"crossref","first-page":"19","DOI":"10.7326\/0003-4819-147-1-200707030-00004","article-title":"Cystatin C as a risk factor for outcomes in chronic kidney disease","volume":"147","author":"Menon","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.thromres.2013.06.011_bb0060","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1111\/j.1532-5415.2006.00828.x","article-title":"Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study","volume":"54","author":"Fang","year":"2006","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.thromres.2013.06.011_bb0065","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.2215\/CJN.02400311","article-title":"Warfarin in atrial fibrillation patients with moderate chronic kidney disease","volume":"6","author":"Hart","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.thromres.2013.06.011_bb0070","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/ki.1990.182","article-title":"Measurement of renal function in chronic renal disease","volume":"38","author":"Levey","year":"1990","journal-title":"Kidney Int"},{"key":"10.1016\/j.thromres.2013.06.011_bb0075","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/S0022-5347(17)67149-0","article-title":"Effect of trimethoprim-sulfamethoxazole on the renal excretion of creatinine in man","volume":"114","author":"Berglund","year":"1975","journal-title":"J Urol"},{"key":"10.1016\/j.thromres.2013.06.011_bb0080","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1053\/ajkd.2000.8237","article-title":"Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment","volume":"36","author":"Coll","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.thromres.2013.06.011_bb0085","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.0954-6820.1985.tb08880.x","article-title":"Serum concentration of cystatin C, factor D and beta 2-microglobulin as a measure of glomerular filtration rate","volume":"218","author":"Grubb","year":"1985","journal-title":"Acta Med Scand"},{"key":"10.1016\/j.thromres.2013.06.011_bb0090","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1056\/NEJMoa043161","article-title":"Cystatin C and the risk of death and cardiovascular events among elderly persons","volume":"352","author":"Shlipak","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2013.06.011_bb0095","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1001\/archinternmed.2009.170","article-title":"Thrombomodulin as a marker for bleeding complications during warfarin treatment","volume":"169","author":"Lind","year":"2009","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.thromres.2013.06.011_bb0100","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","article-title":"Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate","volume":"145","author":"Levey","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.thromres.2013.06.011_bb0105","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2013.06.011_bb0110","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"39","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.thromres.2013.06.011_bb0115","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/01.mnh.0000222694.07336.92","article-title":"Update on cystatin C: new insights into the importance of mild kidney dysfunction","volume":"15","author":"Shlipak","year":"2006","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.thromres.2013.06.011_bb0120","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1111\/j.1523-1755.2004.00517.x","article-title":"Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement","volume":"65","author":"Knight","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.thromres.2013.06.011_bb0125","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0272-6386(03)00406-2","article-title":"Serum cystatin C in the aged: relationships with health status","volume":"42","author":"Wasen","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.thromres.2013.06.011_bb0130","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1681\/ASN.2005050545","article-title":"Cystatin C and mortality risk in the elderly: the health, aging, and body composition study","volume":"17","author":"Shlipak","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.thromres.2013.06.011_bb0135","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.atherosclerosis.2007.09.022","article-title":"Cystatin C is associated with an increased coronary atherosclerotic burden and a stable plaque phenotype in patients with ischemic heart disease and normal glomerular filtration rate","volume":"198","author":"Niccoli","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.thromres.2013.06.011_bb0140","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1053\/j.ajkd.2009.04.024","article-title":"Acute kidney injury during warfarin therapy associated with obstructive tubular red blood cell casts: a report of 9 cases","volume":"54","author":"Brodsky","year":"2009","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1016\/j.thromres.2013.06.011_bb0145","doi-asserted-by":"crossref","first-page":"c142","DOI":"10.1159\/000312877","article-title":"Warfarin therapy that results in an International Normalization Ratio above the therapeutic range is associated with accelerated progression of chronic kidney disease","volume":"115","author":"Brodsky","year":"2010","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.thromres.2013.06.011_bb0150","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ki.2011.44","article-title":"Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate","volume":"80","author":"Brodsky","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.thromres.2013.06.011_bb0155","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1681\/ASN.2008070802","article-title":"Kidney function influences warfarin responsiveness and hemorrhagic complications","volume":"20","author":"Limdi","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.thromres.2013.06.011_bb0160","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1016\/j.jacc.2010.12.033","article-title":"Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients","volume":"57","author":"Roldan","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.thromres.2013.06.011_bb0165","doi-asserted-by":"crossref","first-page":"9","DOI":"10.7150\/ijms.5.9","article-title":"Does eGFR improve the diagnostic capability of S-Creatinine concentration results? A retrospective population based study","volume":"5","author":"Kallner","year":"2008","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.thromres.2013.06.011_bb0170","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2165\/00002512-199914040-00005","article-title":"Safety of treatment with oral anticoagulants in the elderly. A systematic review","volume":"14","author":"Hutten","year":"1999","journal-title":"Drugs Aging"},{"key":"10.1016\/j.thromres.2013.06.011_bb0175","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/02813430601183108","article-title":"Bleeding complications during warfarin treatment in primary healthcare centres compared with anticoagulation clinics","volume":"25","author":"Wallvik","year":"2007","journal-title":"Scand J Prim Health Care"},{"issue":"2","key":"10.1016\/j.thromres.2013.06.011_bb0180","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1161\/CIRCULATIONAHA.112.107128","volume":"127","author":"Piccini","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2013.06.011_bb0185","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1055\/s-0037-1616754","article-title":"Longitudinal stability of coagulation, fibrinolysis, and inflammation factors in stored plasma samples","volume":"86","author":"Lewis","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2013.06.011_bb0190","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1515\/CCLM.2009.121","article-title":"Stability of selected serum proteins after long-term storage in the Janus Serum Bank","volume":"47","author":"Gislefoss","year":"2009","journal-title":"Clin Chem Lab Med"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384813002624?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384813002624?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T08:41:34Z","timestamp":1563352894000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384813002624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S0049384813002624"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2013.06.011","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cystatin C and creatinine as markers of bleeding complications, cardiovascular events and mortality during oral anticoagulant treatment","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2013.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}